Cingulate Inc. (CING)

Market Cap	21.60M
Revenue (ttm)	n/a
Net Income (ttm)	-17.96M
Shares Out	5.41M
EPS (ttm)	-5.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,601
Open	3.980
Previous Close	3.940
Day's Range	3.904 - 4.070
52-Week Range	3.020 - 9.690
Beta	-0.75
Analysts	Strong Buy
Price Target	31.00 (+676.94%)
Earnings Date	Aug 19, 2025

About CING

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety tri...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 8, 2021
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: CING
• Website: https://www.cingulate.com

Analyst Summary

According to 4 analysts, the average rating for CING stock is "Strong Buy." The 12-month stock price target is $31.0, which is an increase of 676.94% from the latest price.

Price Target

$31.0

(676.94% upside)

Analyst Consensus: Strong Buy